| ￥3500 | |
| Z05449-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Human IL17A, His Tag at 2μg/ml (100μl/Well) on the plate can bind IL-17Rc hFc Chimera, Human. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 76.2 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 90-115 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Human IL-17A, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for IL-17Rc hFc Chimera, Human, hFc Tag with the EC50 of 29.8 ng/ml determined by ELISA. »
IL-17Rc hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | IL-17RC (interleukin-17 receptor-like) gene codes for a transmembrane protein, the full length of which inhibits apoptosis in prostate cancer cells. IL-17RC gene transcribes over a dozen different splice variants of mRNA. IL-17RC protein isoforms are differentially expressed in prostatic cells and cancer tissues and may play a negative or positive role in the initiation and progression of prostate cancer. |
| Synonyms | IL-17 receptor C; IL-17RC; IL17Rhom; IL-17RL; ZcytoR14 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
